Will Trump’s drug order put the brakes on China’s overseas pharma drive?
The U.S. president has promised to reduce prescription drug prices by 30% to 80% for Americans, insisting they are entitled to prices paid in other developed countries Key Takeaways: Pharma…
The Nationalism Factor, and a Forced Asset Sale
The huge success of "Ne Zha 2," partly due to national pride, has lit a fire under the stock of the movie's producer, Enlight Media. How important is the nationalism factor when choosing Chinese stocks? And Hong Kong's CK Hutchinson has sold its two port operations in the Panama Canal after coming under pressure from Donald Trump. Are we likely to see more such forced asset sales over national security concerns going forward?
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- What’s Ahead for China Inc. Under Trump 2.0?
- Innogen Pharma jostles for a slice of the weight-loss market
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
WuXi group wrestles with uncertainty over pharma tariffs
2268.HK
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG
